Veradermics (NYSE:MANE) Releases Quarterly Earnings Results

Veradermics (NYSE:MANE) issued its quarterly earnings results on Tuesday. The company reported ($0.56) EPS for the quarter, FiscalAI reports.

Veradermics Stock Down 3.2%

Shares of Veradermics stock opened at $110.72 on Tuesday. Veradermics has a twelve month low of $32.00 and a twelve month high of $131.24. The firm has a market capitalization of $4.63 billion and a PE ratio of -83.88. The firm has a fifty day moving average price of $108.84.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Jefferies Financial Group raised their target price on shares of Veradermics from $138.00 to $182.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Citigroup increased their price target on Veradermics from $135.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Lifesci Capital initiated coverage on Veradermics in a report on Tuesday, June 16th. They set an “outperform” rating and a $135.00 price objective on the stock. Weiss Ratings started coverage on Veradermics in a research note on Tuesday, May 26th. They issued a “sell (d+)” rating for the company. Finally, UBS Group set a $170.00 price target on Veradermics in a research note on Wednesday, July 15th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $153.00.

About Veradermics

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.